Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketmoveralerts.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketMoverAlerts.com.
Recent THC Stock Price: $88.09
Summary: Tenet Healthcare Corp. is an investor-owned health care services company, which owns and operates general hospitals and related health care facilities for urban and rural communities in numerous states, and has offices in California and Florida. The company has investments in other health care companies and is one of the largest investor-owned health care delivery systems in the United States. Tenet Healthcare and its subsidiaries provide healthcare services primarily through general hospitals and related healthcare facilities. Its hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies; intensive care, critical and coronary care units; physical therapy along with orthopedic, oncology, and outpatient services. The related health care facilities include rehabilitation hospitals, specialty hospitals and long-term care facilities.
David S analyst at Truist Financial reiterates coverage on Tenet Healthcare Corporation (THC) stock in the energy sector with a Buy rating and has set THC's stock price target at $105.
TipRanks.com reports that Tenet Healthcare Corporation currently has 5 analysts offering 12-month price targets on THC and the consensus is a Buy rating with an average stock price target of $103.60. The most recent THC stock price we have is $88.09 and we are not making any THC forecasts at this time.
In addition, TradingView issued a buy rating for THC over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on THC. marketmoveralerts.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on THC, please click here >>
Illumina, Inc., ILMN
Recent ILMN Stock Price: $137.84
Summary: Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.
Catherine Ramsey analyst at Robert W. Baird reiterates coverage on Illumina, Inc. (ILMN) stock in the energy sector with a Hold rating and has set ILMN's stock price target at $146.
TipRanks.com reports that Illumina, Inc. currently has 5 analysts offering 12-month price targets on ILMN and the consensus is a Hold rating with an average stock price target of $140.20. The most recent ILMN stock price we have is $137.84 and we are not making any ILMN forecasts at this time.
In addition, TradingView issued a sell rating for ILMN over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ILMN. marketmoveralerts.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ILMN, please click here >>
Zimmer Biomet Holdings, Inc., ZBH
Recent ZBH Stock Price: $122.80
Summary: Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
Richard Newitter analyst at Truist Financial reiterates coverage on Zimmer Biomet Holdings, Inc. (ZBH) stock in the energy sector with a Hold rating and has set ZBH's stock price target at $135.
TipRanks.com reports that Zimmer Biomet Holdings, Inc. currently has 5 analysts offering 12-month price targets on ZBH and the consensus is a Hold rating with an average stock price target of $132.80. The most recent ZBH stock price we have is $122.80 and we are not making any ZBH forecasts at this time.
In addition, TradingView issued a Neutral rating for ZBH over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ZBH. marketmoveralerts.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ZBH, please click here >>
McKesson Corporation, MCK
Recent MCK Stock Price: $501.35
Summary: McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
Ann Hynes analyst at Mizuho Securities reiterates coverage on McKesson Corporation (MCK) stock in the energy sector with a Hold rating and has set MCK's stock price target at $505.
TipRanks.com reports that McKesson Corporation currently has 5 analysts offering 12-month price targets on MCK and the consensus is a Buy rating with an average stock price target of $557.20. The most recent MCK stock price we have is $501.35 and we are not making any MCK forecasts at this time.
In addition, TradingView issued a Strong buy rating for MCK over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MCK. marketmoveralerts.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MCK, please click here >>
The editors at marketmoveralerts.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketMoverAlerts.com
==============================================================================
